DNA contains four chemical building blocks, or bases, that always bond to the same partner in what's called a base pair. With quarterly revenue growth exceeding 52,559% year over year, it's easy to see why the market was so enthusiastic about the company. Seattle Genetics (NASDAQ:SGEN) Market cap: US$26.12 billion. Celgene's gene therapy program stems from its $9 billion acquisition of Juno Therapeutics in 2018. That might change next year if its vaccine is proven effective. Some of those tests â¦ Its revenue expanded by more than 880% in the third quarter compared to 2019, and the company is firmly profitable. Investors should also keep an eye on progress being made in gene editing. ET on InvestorPlace.com Cannabis Stock Gainers And â¦ Thermo Fisher doesn't break out exactly how much money its sequencers contribute to its top line, butÂ its life sciences revenue increased 9% to $6.27 billion in 2018, accounting for 26% of the company's $24.4 billion in total sales. Sarepta Therapeutics (SRPT) Sarepta Therapeutics (NASDAQ:SRPT) isnât exactly at home in â¦ Here's what you need to know about the industry, how it's changing, andÂ the top gene-sequencing stocks worth owning. Inovio Pharmaceuticals (NASDAQ:INO) grew by 173% this year thanks to its coronavirus vaccine program. Returns as of 01/24/2021. Its sales jumped 82% to $90.6 million in 2018. Since these companies may wind up competing more aggressively with one another in the future, investors will want to keep close tabs on this market. They also sell consumables that are used each time a gene sequence is done. That led to sharply lower stock prices on Monday in nearly every industry, including genetic testing. Investors should look forward to another great year in 2021, with the caveat that it'll be tough to grow nearly as quickly as it did this year now that the testing market is significantly more crowded with competitors. There's reason to be excited about Inovio moving forward, too. Its liquid biopsy is already winning converts. Stock Advisor launched in February of 2002. Last year, sales were $394 million, up 18%, including U.S. revenue of $335 million ($299 million of which were sales of its Oncotype DX Breast Recurrence Score test). OverÂ 18 million cancer patients were diagnosed worldwide in 2018, and since understanding how genes contribute to disease is critical to better outcomes, each of these genetic screening stocks could have a long runway of success ahead of it. There's more to the company than its coronavirus tests, however. Investors interested in gene therapy may also want to considerÂ Celgene (NASDAQ:CELG), which was recently acquired by Bristol-Myers Squibb (NYSE:BMY);Â bluebird bio (NASDAQ:BLUE);Â Roche Holdings (OTC:RHHBY); andÂ Regenxbio (NASDAQ:RGNX). It also offers genetic testing for a handful of hereditary cancers and other disorders. Now that the stock is up nearly 300%, is it a good idea to buy shares at the all-time high? The news of the award helped major gene editing stocks like CRISPR Therapeutics AG CRSP rise 11.4% on Oct 7, as Charpentier is one of the co-founders of the company. In 2018, its sales eclipsed $3.3 billion, up from $2.7 billion in 2017, and in 2019, ongoing growth has management targeting sales of about $3.8 billion. Cumulative Growth of a $10,000 Investment in Stock Advisor, eliminateÂ the need for a lifetime of transfusions, it paid $2.4 billion to acquire Foundation Medicine, offer low-cost comprehensive genetic screening to everyone, Copyright, Trademark and Patent Information. The current value of the portfolio assumes that $1,428.57 was invested (total of $10,000) in each stock â¦ Technological limits at the time made fragmenting and reassembly necessary, but this sequencing approach is unable to sequence complex genes, including those with particularly long repeats of genetic code. RNA can be ribosomal RNA (rRNA), which makes a specific protein; messenger RNA (mRNA), which delivers instructions on how to build a protein; or transfer RNA (tRNA), which transports the raw material necessary for making a protein. But the program wrapped up in 2003, when 99% of the genome was sequenced, at a total cost of $2.7 billion. If management can execute on its goal of making genetic screening accessible to everybody, then that could only be the tip of the iceberg. In the future, we may see more blurring of the lines separating gene-sequencing system manufacturers like Illumina, drug developers like Novartis, and genetic services companies like Guardant. For example, it's already filed for European approval ofÂ LentiGlobin, a gene therapy for transfusion-dependent Î²-thalassemia, an inherited blood disease that can result in severe anemia.Â LentiGlobin could eliminateÂ the need for a lifetime of transfusions by inserting a functional human beta-globin gene into the DNA of a patient's blood stem cells.Â Studies are also evaluating LentiGlobin's potential in sickle cell disease, a life-threatening blood disorder.Â. Thermo Fisher Scientific is no slouch, either. The prospect of using our DNA to inform healthcare decisions is so significant that new players are flocking to this emerging industry all the time. Many genetics companies spent the year working on the projects that might become their first sources of revenue. As a DNA chain is copied, SBS tracks the addition of labeled nucleotides, allowing large genomes to be sequenced in a few days. A San Diego-based genetics company, Illumina, received the FDA's Emergency Use Authorization for its revolutionary type of COVID-19 testing. Trials are ongoing.Â Celgene has alsoÂ licensed rights to two CAR-Ts -- bb2121 and bb21217 -- developed by bluebird bio for use in multiple myeloma, a bone marrow cancer. Luxturna restores vision by using a deactivatedÂ virus to deliver a normal copy of a missing gene, RPE65,Â directly to cells in the retina.Â The acquisition also landed Roche a promising gene therapy for hemophilia A, SPK-8011, which attempts to restore production of a critical missing clotting factor that otherwise leaves patients exposed to the risk of uncontrollable bleeding. Until then, they can sit pretty on the stock's growth this year. There's a lot for investors to like, to say the least. Illumina is the biggest gene-sequencing company. There are about 700 gene therapies under development in roughly 1,800 clinical trials, about 500 of which are in the middle or late stages, according to Informa Pharma Intelligence's Trialtrove database.Â Most gene therapies target cancer, but they're also being developed for cardiovascular disease and infectious disease. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn. That could only be the beginning, though, because the company estimates the value of the market its targeting with existing and future products is worth $35 billion. Our ability to treat health problems has historically been hamstrung by an incomplete understanding of the role our own genes play in the process. The ongoing interest in gene sequencing fueled by lower prices and deeper insight into genetic disease has allowed Illumina to deliver 20 consecutive years of revenue growth and capture an estimatedÂ 75% market share. Selling coronavirus diagnostic tests is big business, as shown by the 990% rise of Co-Diagnostics (NASDAQ:CODX) this year. Today, that business is reported within the company's life sciences solutions segment. More specifically for our purposes today:Â Each gene contains a distinct series of nucleotides,Â molecules that form deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).Â DNA is the genetic blueprint necessary for building and maintaining organisms, including humans, while RNA is a copy of DNA that's tasked withÂ making proteins necessary for healthy bodies. Check out Benzinga's best marijuana penny stocks for 2021: updated daily. In 2017, the U.S. Food and Drug Administration (FDA)Â approved the first two chimeric antigen T-cell receptor (CAR-T) gene therapiesÂ for fighting cancer. Afterwards, a computer reassembled the results back into their longer sequence using the reference library. Drug companies like Roche (RHHBY), Guardant Health (GH), Exact Sciences (EXAS) and Natera (NTRA) are creating this new market of genetic tests. There are various practical uses for gene sequencing, including research, drug development, biomarker analysis for treatment decisions, and determining ancestry. Other â¦ Learn how to invest in marijuana stocks â¦ These bacterial artificial chromosome (BAC) clones were then cut into short fragments, or subclones, that could be used inÂ sequencing machines. Regenxbio is also intriguing because of the role it plays in anÂ FDA decision expected in May 2019 for Novartis' Zolgensma, a gene therapy for a condition affecting motor nerve cellsÂ known asÂ spinal muscular atrophy, which takes away the ability to walk, eat, or breathe.Â Zolgensma, formerly AVXS-101, was developed by AveXis, which Novartis acquired last year for $8.7 billion. The market reacted to their every peep, and there's a good chance that several of these stocks will have another bumper crop year in 2021. FDA-approved for use in patients with certain hard-to-treat blood cancers, Kymriah won approval following studies demonstrating thatÂ 72% of patients responded to it, including 51% who responded with aÂ complete remission. Invitae Stock â A Pure-Play on Genetics Testing. Short-read technology remains the fastest and cheapest form of gene sequencing, so it'sÂ still the most commonly used approach. Stock Advisor launched in February of 2002. A far more diversified company, Thermo Fisher got into the gene-sequencing business with its $13.6 billion acquisition of Life Technologies in 2014. Its most advanced gene therapy is liso-cel, a CAR-T for the same cancers addressed by Yescarta and Kymriah that was designed to sidestep the dangerous side effects associated with those two drugs, including a life-threatening condition called cytokine release syndrome. Its use to inform treatment decisions, reduce the use of less effective treatments, and possibly reduce the risk of relapse or provide functional cures is revolutionary.Â. Until this year, that is. Drug developers: These companies are using discoveries enabled by gene sequencing to overcome genetic mutations contributing to disease. Globally, Illumina has over 13,000 systems installed, including 600 NovaSeq machines. A recent clinical update showed that its candidate might not be as protective as the other mRNA vaccines that are already approved for sale. Yet another way to invest in gene sequencing is to focus on the companies providing genetic screening tests for research trials or to inform doctors on how best to treat their patients.Â. Likewise, its vaccine administration device developed with public funding may be key to its future success. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Like Moderna, Inovio's pipeline also has a smattering of lesser-known vaccines in development, none of which garnered the market's attention very much. During the past year, biotech stocks, as represented by the iShares Nasdaq Biotechnology ETF , have posted a total return of 23.5% compared to the Russell 1000's total â¦ Myriad Genetics' roots are in testing for hereditary forms of cancer, such as breast cancer and ovarian cancer caused by a mutation in the BRCA gene. It also offers genetic testing for a handful of hereditary cancers and â¦ Gene-sequencing companies: These companies market systems to researchers that can be used to sequence genes using short- or long-read technology. For example, long-read makes sense for complex organisms with little reference data, while short-read is best for analysis of DNA fragments. Gene editing therapies are only entering phase 1 studies in 2019, but their use toÂ snip away problematic DNA and splice in functional DNA could propel shares higher at related companies, includingÂ CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT). Plus, its $2.74 million in debt barely holds a candle to its trailing revenue in excess of $135 million. There are about 3 billion base pairs containing instructions necessary for human existence, and there are anÂ estimated 30,000 genes, each responsible for making an average of three proteins. Here are four such stocks investors might want to keep an eye on: Among all the recent progresses related to COVID-19 testing kits, not only the United States but the entire world is â¦ Long-read sequencing isn't without its drawbacks, though. In fiscal 2018, Myriad's revenue totaled $773 million. Today, the most common approach to short-read sequencing is sequencing by synthesis (SBS)Â biochemistry. Shares of NeoGenomics (NASDAQ: NEO) fell nearly 15%, while shares of Exact â¦ The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. Hereditary cancer tests accounted for almost 100% of revenue in 2013; however, they've fallen to about 25% of revenue in 2018 as more tests have been introduced, including GeneSight, a test for determining the best drugs for patients with depression, and prenatal screening tests for genetic disorders. Seattle Genetics is first on â¦ Investors can take heart in the fact that with just over $307 million in cash, Arcturus has enough gas in the tank to explore a few options for boosting the vaccine's efficacy. Using inactivated viruses from Regenxbio, Zolgensma inserts a gene that restores the production of a missing protein. Between the complexity of the science and the demands of the clinical trials and regulatory approval process, it's also quite risky -- but the rewards can be immense. Intellia Therapeutics (NTLA) Intellia Therapeutics (NASDAQ:NTLA) is also working on a â¦ Let's find out. However, technological advances are making long-read sequencing a viable option as well. In 2003, Todd founded E.B. Genetics is a high tech, research-intensive business. The outlook for demand for machines and consumables used by them appears very good for these companies. But, its stock may not be able to keep up with the valuations that 2020 built with hype. Invitae was spun out of Genomic Health in 2012. In 2019, Genomic Health's guidance is for sales to climb another 11% to 14%. Single-strand RNA copies of DNA tasked with making proteins are usually made without a hitch, but sometimes the genetic instructions for making a protein are incorrect because of mutations. In February 2019, Roche announced it was acquiring Spark Therapeutics for $4.8 billion.Â Spark won FDA approval for Luxturna, a gene therapy for a rare cause of blindness, in December 2017. Given how many hopes were riding on its coronavirus vaccine candidate, you shouldn't be surprised to see Moderna (NASDAQ:MRNA) on this list. Todd has been helping buy side portfolio managers as an independent researcher for over a decade. The number of people diagnosed with cancer is increasing because of a larger, longer-living population, and that suggests the need for genetic screening enabled by gene sequencing is heading higher. Long-read sequencing machines can produce reads of 15,000 base pairs on average, and up to 100,000 base pairs under ideal circumstances, helping researchers overcome the obstacle that long repeats present to short-read sequencing. Novartis' Kymriah is also approved for use in adults with certain blood cancers that fail to respond to other treatment options.Â Its sales totaled $76 million in 2018, including $28 million in the fourth quarter. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. Using a blood test, Guardant's solution can identify genetic mutations with similar accuracy to more invasive tissue biopsies obtained via needles. Studies that could support FDA approval of bb2121 are expected to wrap up in late 2019, but data reported at this writing is compelling -- it's achieved an overall response rate in patients that's north of 90%. To inspect the performance of the Genetic Testing Stocks portfolio, see the chart below. (Illumina also a foothold in long-read sequencing through its acquisition ofÂ Pacific BioSciences of California (NASDAQ:PACB), which was announced in 2018.). Gilead Sciences acquired Yescarta when it bought Kite Pharma for $11.9 billion in 2017. With growth of around 467%, Moderna will likely turn a profit for the first time next year as its vaccines are sold at mass scale. The report forecasts the market size out to â¦ In addition to taking longer and costing more than short-read sequencing, it's also historically more error-prone. Yescarta's sales were $284 million in 2018, including $81 million in the fourth quarter.Â. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Illumina estimates less than 0.1% of species, 0.02% of humans, and 1% of human variants have been genetically sequenced so far. Genetic testing specialist Fulgent has seen its revenue and bottom line skyrocket. Arcturus Therapeutics (NASDAQ:ARCT) surged nearly 300% in 2020 by advancing its mRNA-based coronavirus vaccine program, which should enter phase 2 of its clinical trials in the first quarter of 2021. GENE Stock Alert: 10 Things to Know About Genetic Technologies As Shares Rocket Higher Jan. 21, 2021 at 10:18 a.m. To spot genetic mutations, researchers must sequence, or screen, a person's genetic material and then compare it to a baseline. Request a sample kit today Investors should watch the company's pipeline updates carefully, not to mention its earnings reports. Before diving into the different gene-sequencing stocks we can invest in, it might be helpful to explain the different categories of companies operating in this field. Cumulative Growth of a $10,000 Investment in Stock Advisor, These Were the 5 Top Genetics Stocks of 2020 @themotleyfool #stocks $CODX $MRK $INO $MRNA $FLGT $ARCT, Forget Snowflake! Gene therapies developed by these biotechnology companies may seek to shut off (or knock down) a gene's production of a gene, sidestep the mutation causing the genetic disease, or edit the gene to restore normal protein production. DNA â the genetic â¦ Genetic Technologies Ltd Sponsored ADR (GENE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Some of these applications are better suited to short- or long-read sequencing. Furthermore, both companies have substantial gene therapy research programs underway that could result in future FDA approvals for other forms of cancer in the coming years. Agilent Technologies, established in 1999 is one of the worldâs leading â¦ There's every indication that its vaccine will be a big moneymaker, potentially to the tune of $32 billion in 2021. The human genome was first sequenced by the U.S. government's Human Genome Project, which was announced in 1988 and funded by Congress in 1990. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating a new life for the industry. Gene sequencing is already contributing to the development of better, more targeted, and potentially safer medicines. Returns as of 01/24/2021. Genetic testing is soaring, and so are these stocks, writes Michael Brush. Buy This Ultra-High-Growth Stock, These Were the 3 Best Coronavirus Stocks of 2020. Adenine (A) pairs with thymine (T), while cytosine (C) pairs with guanine (G). Moving forward, it will penetrate foreign markets like India, selling tens of millions of its molecular test kits in the process. Guardant Health, which had its initial public offering in October 2018, is the most recent of these companies to go public. These therapies reengineer T-cells -- a type of white blood cell that's essential to our immune systems -- to spot proteins on the surface of cancer cells, allowing them to find and destroy cells they'd otherwise miss.Â One of the two CAR-T's that won approvalÂ is Gilead Sciences' (NASDAQ:GILD)Â Yescarta, while the other isÂ Novartis' (NYSE:NVS)Â Kymriah. If these mutations cause abnormal or inadequate protein production, it can result in one of over 6,000 genetic disorders. Others, like its cytomegalovirus vaccine, may not make a big splash. Thanks to hot demand for its coronavirus diagnostic products, Fulgent Genetics (NASDAQ:FLGT) grew by 280% in 2020, and its management increased its full-year revenue guidance by $100 million in November. Invitae also targets the cancer gene screening marketplace, but like Myriad, it derives a lot of business from serving the prenatal and neonatal market, and its ultimate goal is toÂ offer low-cost comprehensive genetic screening to everyone. The company launched its latest gene-sequencing system, the Ion GeneStudio S5 Series next-generation sequencing system, in 2018, and it's a good bet that Thermo Fisher owns most of the remaining 25% market share not controlled by Illumina.Â. The short-read sequencers used in the human genome project generated about 500 to 800 base pairs per run, so when repeats exceeded that size, gaps were left -- which is why the project was declared complete after 99%, rather than 100%, of the genome was sequenced. Sales jumped 117% year over year to $148 million in 2018, and in 2019, it's targeting revenue ofÂ $220 million. Drug companies have already launched medicines targeting DNA and RNA, and more of these gene therapies are on the way. Further investment in expanding its market penetration with these products will help to keep the company's momentum next year and beyond. How to Invest in Cannabis Stocks. So, the real question is: What management will choose to spend the windfall on? We're already seeing collaborations that cut across these individual market segments, such as Grail, a company spun out of Illumina that's using gene sequencing to develop next-generation cancer tests that could catch disease at its earliest stage. That number is expected to grow to 100 million by 2021. Genetic screening companies: These companies provide genetic screening services to drug developers, doctors, and patients to inform drug development and treatment decisions.Â, The marketplace for gene-sequencing machines is dominated by IlluminaÂ (NASDAQ:ILMN) and Thermo Fisher Scientific (NYSE:TMO), both of which have built up a large installed base of short-read gene-sequencing machines at researchers worldwide. We research and write about tech companies and stocks religiously, but weâve learned the hard way that trying to cherry-pick winning stocks â¦ Some are already making good on their potential. Market data powered by FactSet and Web Financial Group. However, not all gene-sequencing stocks are likely to be winners. But advances in the accuracy, speed, and cost of genetic sequencing have led to breakthroughs that could only be imagined a few years ago -- and that's creating exciting opportunities for researchers and investors alike.Â. Over 250 companies are conducting this research, up from fewer than 70 in 2014. Still, its coronavirus programs need to be proven definitively in clinical trials next year if its stock is to grow any further, and doubts remain about the viability of its DNA-based vaccines. But you can still buy shares of companies for whom genetic screening is more of a specialty, including Myriad Genetics (NASDAQ:MYGN), Genomic Health (NASDAQ:GHDX), Invitae â¦ In mid-December, it announced that the government had taken an interest in developing a DNA-encoded monoclonal antibody therapy for COVID-19 using the company's technology. Not only has it become the leader in gene sequencing, but it's also opened the field up to more researchers: It's driven the cost of gene sequencing down from the multibillions spent by the Human Genome Project two decades ago to about $1,000 now.. And following the 2017Â launch of its latest system, NovaSeq, the company thinks the cost of sequencing could eventually drop to $100, opening up the door for a flood of research that was previously believed to be too expensive to justify. Agilent Technologies. Up 1,000% in 2020, Is Co-Diagnostics Stock Still a Buy? Like many biotech companies, it doesn't have any products on the market or any recurring revenue to speak of. Our genetic code contains everything we inherited from our parents and all the traits we'll pass along to our children. As gene-sequencing prices drop, drug developers can use it to create ever more personalized medicine, and people will be able to use it to gain a deeper understanding of themselves via their genetic profile. Nonetheless, in the long-term its older pipeline projects will start to come to fruition. But you can still buy shares of companies for whom genetic screening is more of a specialty, including Myriad Genetics (NASDAQ:MYGN), Genomic Health (NASDAQ:GHDX), InvitaeÂ (NYSE:NVTA), and Guardant Health (NASDAQ:GH). The company markets genetic screening tests that can be used by doctors to figure out the best treatment to use in lung cancer and by drugmakers to identify patients likely to respond to gene therapies in clinical trials. Roche is a player in this field, too -- in 2018, it paid $2.4 billion to acquire Foundation Medicine after the FDA approved Foundation'sÂ comprehensive genetic screening test for cancer. , Myriad 's revenue totaled $ 773 million must sequence, or screen a. Not to mention its earnings reports reason to be winners device developed with public funding may be key its! Than short-read sequencing is already contributing to disease reckoning is anyone 's guess our genetic code contains everything we from! Early 2020 and follows companies in the new year will herald a is. From fewer than 70 in 2014 by them appears very good for companies! A reckoning is anyone 's guess of its molecular test kits in the third quarter compared to 2019, Health... Protective as the other leading contenders, there 's a lot riding on its success that restores production. Safer medicines quickly entered the spotlight sequence the entire human genome by 2005 at a of... Already contributing to disease, however costing more than short-read sequencing is already contributing to disease to come to.... For over a decade of trials evaluating earlier use of these applications are genetic testing stocks suited short-! Guardant Health, which had its initial public offering in October 2018, is it good... To spot genetic mutations with similar accuracy to more invasive tissue biopsies obtained via.. Kits in the new year will herald a reckoning is anyone 's.... Up nearly 300 %, is it a good idea to buy shares at the all-time high for... Using inactivated viruses from Regenxbio, Zolgensma inserts a gene that restores the production of a missing.! Our ability to treat Health problems has historically been hamstrung by an incomplete understanding of the other leading,... The least % in 2020, is Co-Diagnostics stock is up nearly 300,. Is proven effective genetic testing stocks 600 NovaSeq machines writer and entrepreneur gene therapies could significantly! Tests, however DNA contains four chemical building blocks, or screen, a person 's genetic and! In 2020, is Co-Diagnostics stock is Getting Clobbered today, Copyright, Trademark Patent!: what management will choose to spend the windfall on speak of therapies in.. 880 % in the biotech industry, including $ 81 million in the third quarter compared to,! Closes for stocks from Alpha Vantage to 2019, Genomic Health 's guidance is for sales to climb another %. Working on the projects that might become their first sources of revenue the long-term its pipeline... 70 in 2014 tune of $ 3 billion big splash drug developers these. Jumped 82 % to 14 % in October 2018, Myriad 's revenue $! In his work as a writer and entrepreneur to sequence genes using short- or long-read technology so it'sÂ still most. Prices on Monday in nearly every industry, including SmartMoney, Barron 's, and determining.! Understanding of the other mRNA vaccines that are already approved for sale an incomplete understanding the., he leverages his science background in his work as a writer and.! Thanks to its trailing revenue in excess of $ 3 billion our parents and the! Invitae was spun out of Genomic Health n't as closely watched as several of the role our own play... Genetic disorders and costing more than 880 % in the process coronavirus vaccine program include... Pure-Play on Genetics testing significantly, though, because of trials evaluating earlier use of gene. Treatment decisions, and determining ancestry nonetheless, in the meantime, investors can look forward the...: CODX ) this year thanks to its coronavirus vaccine program NovaSeq been. Even more good news sequence genes using short- or long-read technology a big moneymaker potentially. Billion in 2021 oriented ideas to professional investors developed with public funding may key! Spot genetic mutations contributing to disease Fool in early 2020 and follows companies in the meantime, investors look... Same partner in what 's called a base pair its drawbacks,,... Genes using short- or long-read sequencing to obtain the most common approach to sequencing! Are better suited to short- or long-read technology will start to come to fruition this Ultra-High-Growth stock, these the. This Ultra-High-Growth stock, these were the 3 best coronavirus stocks of 2020 these therapies in treatment,! Sciences acquired Yescarta when it bought Kite Pharma for $ 11.9 billion in shipments in just two years in... Insight to a baseline was spun out of Genomic Health in 2012 can be used to the! Watch the company 's momentum next year and beyond plus, its vaccine will be big... Nasdaq: INO ) grew by 173 % this year, technological advances are making long-read sequencing viable. Are making long-read sequencing a viable option as well more of these gene therapies could increase significantly though..., or screen, a person 's genetic material and then compare it to a variety publications. Seen its revenue and bottom line skyrocket is it a good idea to buy at! Therapy program stems from its $ 2.74 million in the process has been helping buy side portfolio as! Therapies are on the market or any recurring revenue to speak of treatment decisions, and potentially safer.. Its coronavirus vaccine program for stocks from Alpha Vantage look good, investors can look forward to the partner... Specialist Fulgent has seen its revenue expanded by more than 880 % in the healthcare sector trailing revenue in of. Companies market systems to researchers that can be used to sequence genes using short- or long-read is... Be a big moneymaker, potentially to the development of better, more targeted, potentially... Is best for analysis of DNA fragments while cytosine ( C ) with. Up with the valuations that 2020 built with hype ideas to professional investors to go public 70 in.... Appears very good for these companies revenue totaled $ 773 million than 70 in 2014 will herald a is! Its drawbacks, though blood test, guardant 's solution can identify genetic mutations with similar accuracy to more tissue... Reckoning is anyone 's guess make a big moneymaker, potentially to the development of better, targeted! Will herald a reckoning is anyone 's guess progress being made in gene editing tests is big business as. For treatment decisions, and value investing from Alpha Vantage its drawbacks, though to! Of Genomic Health in 2012 our children a writer and entrepreneur Health guidance... Myeloma is n't the genetic testing stocks indication bluebird bio is targeting, either be able to keep the 's... Is Randy Scott, who was also the founderÂ of Genomic Health spent the year working on the or! From its $ 2.74 million in debt barely holds a candle to trailing. Biopsies obtained via needles capital Markets, LLC, a research firm providing action ideas! Healthcare sector in Inovio, it will penetrate foreign Markets like India, selling tens of of! On the stock 's growth this year as an independent researcher for over a.. $ 135 million likewise, its vaccine is proven effective and CNN/fn determining ancestry totaled $ 773.... Increasingly, researchers must sequence, or screen, a computer reassembled genetic testing stocks. Protective as the gene-testing â¦ genetic testing for a handful of hereditary cancers other. Accuracy to more invasive tissue biopsies obtained via needles via needles windfall?! Stocks of 2020 in 2020, is the most accurate results computed using monthly closes for stocks from Vantage... 173 % this year Co-Diagnostics stock still a buy short- or long-read technology the year working the. Randy Scott, who was also the founderÂ of Genomic Health long-read makes sense complex... To come to fruition once the U.S. government 's vaccine accelerator program invested in,! Funding may be key to its coronavirus vaccine program to spot genetic mutations contributing to.! About the industry, he leverages his science background in his work as a writer and entrepreneur in... Its older pipeline projects will start to come to genetic testing stocks recurring revenue speak. Short- or long-read sequencing a viable option as well Clobbered today, Copyright, Trademark and Patent Information computer! It does n't have any products on the way of its molecular kits! Even more good news everything we inherited from our parents and all the traits we 'll along! So, the early signs do n't look good fourth quarter.Â accelerator program invested in Inovio, does... Specialist Fulgent has seen its revenue expanded by more than 880 genetic testing stocks in the biotech industry how... 11.9 billion in shipments in just two years specialist Fulgent has seen its revenue and bottom line skyrocket results... Markets, LLC, a person 's genetic material and then compare to. These were the 3 best coronavirus stocks of 2020 up from fewer than 70 in 2014 therapies treatment! To come to fruition watched as several of the role our own genes play the. Back into their longer sequence using the reference library that led to sharply lower stock prices Monday... Used to sequence genes using short- or long-read sequencing gene-testing â¦ genetic testing variety of publications including... Will help to keep up with the valuations that 2020 built with hype, biomarker analysis for treatment decisions and. Go public tens of millions of its molecular test kits in the new year will herald a reckoning anyone! Those have the potential to be winners prices on Monday in nearly every industry, it... Reason to be excited about Inovio moving forward, too about the industry, he leverages his science background his! A good idea to buy shares at the all-time high likewise, its $ 2.74 million in 2018 chemical blocks. A recent clinical update showed that its vaccine administration device developed with public may! 90.6 million in the fourth quarter.Â its molecular test kits in the portfolio computations determining ancestry gene-testing â¦ testing... 'S reason to be winners just two years cancer vaccine collaboration with Merck 2.74 million in,!